Physiopathology, Diagnosis, and Treatment of Diabetes Insipidus

Author(s):  
Ana M. Ramos-Leví ◽  
Mónica Marazuela
2018 ◽  
Vol 2018 ◽  
pp. 1-5
Author(s):  
Shinsaku Imashuku ◽  
Miyako Kobayashi ◽  
Yoichi Nishii ◽  
Keisuke Nishimura

Diagnosis and treatment of Langerhans cell histiocytosis (LCH) in elderly patients are often difficult. We report here a 61-year-old female suffering from a refractory axillary ulcer for nearly a year, whose biopsy revealed LCH. It was also noted that the patient had other cutaneous papulovesicular eruptions of LCH as well as central diabetes insipidus. The patient was first successfully treated with multiagent chemotherapy (cytosine arabinoside/vinblastine/prednisolone). DDAVP also well controlled diabetes insipidus; however, the axillary ulcer and cutaneous LCH relapsed. Thereafter, we found topical imiquimod to be effective in the treatment of relapsed cutaneous LCH lesions.


2005 ◽  
Vol 5 (2) ◽  
pp. 38-42 ◽  
Author(s):  
Elvedina Kapić ◽  
Fahir Bečić ◽  
Maida Todić

In this paper we have reviewed the possition of desmopressin in the treatment of diabetes insipidus. Desmopressin is a synthetic analog of vasopressin, with more pronounced antidiuretic effect. It is treatment of choice in substitution therapy of diabetes insipidus. Its application before sleeping time can reduce nocturnal enuresis, so it has a place in the treatment of enuresis nocturna. Antidiuretic effect of desmopressin is the result of agonistic effect on V2 receptors in the renal tubules. The efficacy and safety of desmopressin in mentioned indications was confirmed in clinical studies.


BMJ ◽  
1975 ◽  
Vol 4 (5997) ◽  
pp. 652-652
Author(s):  
N D Walsh

Sign in / Sign up

Export Citation Format

Share Document